Rheumatic Disease
Women with rheumatic diseases want rheumatologists involved in sexual, reproductive health
Steroid use increases COVID-19 hospitalization risk for patients with rheumatic diseases
Patients with rheumatic disease, COVID-19 more likely to require ventilation
Reflections on COVID-19 Across Generations

These are unparalleled times indeed. We believe over the next number of weeks and months, the events unfolding now will represent a defining time for our profession and our society. As we write this in March 2020, we are approaching the maelstrom of the epidemic and bracing for events that cannot be predicted with great accuracy.
Mindset Matters: Harnessing the Placebo Effect for Patient Benefit
To a nonmedical professional, the placebo effect is a fairly straightforward concept: give someone a sugar pill, tell them it is medicine, they think they get better. But the reality of what the placebo effect has come to mean in the current health care setting is something entirely different, and more complicated.
Prime-boost vaccination enhances immunogenicity in patients with rheumatic disease

Patients with inflammatory rheumatic disease receiving conventional DMARDs and a prime-boost vaccination strategy — a dose of pneumococcal conjugate vaccine and a dose of 23-valent polysaccharide vaccine — saw improved immunogenicity, compared with single pneumococcal conjugate vaccination, according to data published in Arthritis Research & Therapy.
United Rheumatology meeting 'opens the conversation' between rheumatologists, payers

The United Rheumatology Spring National Meeting will offer attendees lectures on cutting edge topics such as genomics and transcriptomics in addition to a range of continuing medical education activities. But the real appeal of United Rheumatology, and of the meeting, will be the guidance that can be provided to independent rheumatologists regarding practice management strategies and interacting with payers.
Lupus gut dysbiosis, high disease activity a ‘vicious cycle’
ACR releases first ever guideline on reproductive health in rheumatic disease
Low-dose methotrexate linked to skin cancer, various adverse events

Low-dose methotrexate — the most commonly used drug for systemic rheumatic diseases — was associated with small to moderate increased risks for skin cancer along with gastrointestinal, infectious, pulmonary and hematologic adverse events, according to a study published in the Annals of Internal Medicine.